XTAE
PLUR
Market cap17mUSD
, Last price
Name
Pluri Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.74%
Rev. gr., 5y
125.33%
Revenues
1m
+309.82%
Net income
-23m
L+8.11%
CFO
-18m
L+1.05%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Haifa, Israel, and established in 2001, Pluri Inc. is a biotechnology company dedicated to advancing placenta-derived cell therapies. Its primary goal is to address a spectrum of health issues, including inflammatory conditions, muscle damage, and blood disorders. The company's core development involves placental expanded (PLX) cell products. A leading candidate, PLX-PAD, is currently in a Phase III clinical trial to improve muscle recovery following hip fracture surgery. It is also undergoing a Phase I/II trial, in partnership with Tel Aviv Sourasky Medical Center, for the treatment of steroid-refractory graft versus host disease. Furthermore, PLX-PAD has successfully completed a Phase II clinical trial for acute respiratory distress syndrome linked to COVID-19 and a Phase I trial for patients with incomplete recovery after bone marrow transplantation. Another key product, PLX-R18, is being developed to aid in the recovery of blood cell production following hematopoietic cell transplantation. Pluri is also collaborating with the National Institutes of Health and the U.S. Department of Defense to create a therapeutic solution for acute radiation syndrome. The company, formerly known as Pluristem Therapeutics Inc., adopted its current name, Pluri Inc., in July 2022.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||